

DARA Biosciences, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
NEW YORK, NY--(Marketwire - April 5, 2011) - [ Taglich Brothers, Inc. ] is pleased to announce that Richard Franco, President & CEO of [ DARA BioSciences, Inc ]. (
About Taglich Brothers
[ Taglich Brothers, Inc ]. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
About DARA BioSciences, Inc.
[ DARA BioSciences, Inc. ] is a North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA advancing through clinical development: 1. KRN5500 for the treatment of neuropathic pain; and 2. DB959 for the treatment of type 2 diabetes. In addition, the Company has a pipeline of diverse drug candidates at various stages of development, with 88 US and foreign granted patents and 60 pending applications. DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities.